Loading…
Largest independent provider of home and alternate-site infusion therapy services in the United States.
Largest independent provider of home and alternate-site infusion therapy services in the United States.
Buys infusion drugs, supplies them to patients' homes and bills health insurers and government programmes for the drugs and the nursing visits that give them, so revenue is mostly drug cost while profit comes from a margin on top. It took its current form in 2019, when BioScrip merged with Option Care.
Moat: narrow (scale, distribution, regulatory licence). Largest national home-infusion network and payer contracts create scale hard for smaller regional providers to match.
Headquarters: Bannockburn, Illinois · Founded: 2015 · Employees: 6,528
Size Option Care Health (OPCH) is a United States Health Care company (Medical/Nursing Services) with a market value of $4.74B, the 1218th largest of 3,117 United States companies the cockpit tracks. Shares closed at $31.65 on 6 Nov 2026.
Performance Over six months the shares gained 54.3%, against +25.8% for the median peer and -1.1% for the United States market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 4.0% over the last twelve months (peer median +12.8%); the operating margin is 5.9% (peer median 8.9%).
Valuation It trades at 15.6× forward earnings against a peer median of 35.0× (3rd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.9 points above its cost of capital (6.8% WACC).
Short interest Short interest is 4.8% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $5.75B | $5.65B | $5.00B | $4.30B | $3.94B |
| Revenue growth | — | +13% | +16% | +9% | — |
| Gross profit | $1.03B | $1.02B | $952M | $922M | $806M |
| EBITDA | $412M | $409M | $385M | $377M | $325M |
| Net income | $215M | $208M | $212M | $267M | $151M |
| Free cash flow | $279M | $217M | $288M | $329M | $232M |
| Capital expenditure | $40.5M | $41.3M | $35.6M | $41.9M | $35.4M |
| Total debt | $1.26B | $1.27B | $1.22B | $1.17B | $1.16B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Option Care Health OPCH | $4.74B | +54% | +4% | 6% | 15.6× | 1.5% |
| CVS Health CVS | $107B | -7% | +7% | 4% | 9.9× | -3.9% |
| BrightSpring Health Services BTSG | $13.4B | +22% | +23% | 4% | 28.3× | 24.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | OPCH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.9% | +8.7% | 4th lowest of 21 |
| 6-month return | +54.3% | +25.8% | 5th highest of 20 |
| Distance from 52-week high | -14.0% | -14.2% | 11th highest of 21 |
| Revenue growth (TTM) | +4.0% | +12.8% | 7th lowest of 21 |
| Operating margin | 5.9% | 8.9% | 6th lowest of 21 |
| Forward P/E | 15.6× | 35.0× | 3rd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 1.5% | 17.1% | 2nd least demanding of 19 |
| Growth delivered (Del g) | +13.2% | +12.5% | 9th highest of 19 |
| Hurdle (Req g minus delivered) | -11.8 pp | +1.9 pp | 3rd least demanding of 19 |
| ROIC minus cost of capital | +4.9 pp | +0.9 pp | 6th highest of 21 |
| EV / EBITDA | 13.9× | 14.6× | 8th cheapest of 15 |
| Net debt / EBITDA | 2.3× | 3.0× | 7th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Option Care Health OPCH | United States | $4.74B | +54% | +4% | 6% | 15.6× | 1.5% | +13.2% |
| Lifestance Health LFST | United States | $5.26B | +79% | +20% | 5% | 62.6× | 37.8% | +30.4% |
| BillionToOne BLLN | United States | $5.38B | +54% | +90% | 11% | 144.4× | 26.8% | +90.1% |
| Concentra Group Holdings Parent CON | United States | $5.38B | +75% | +14% | 17% | 24.5× | 3.9% | +7.9% |
| Medicover MCOV-B.ST | Sweden | $4.14B | +36% | +6% | 7% | 38.3× | 20.8% | +20.2% |
| RadNet RDNT | United States | $5.98B | +31% | +19% | 5% | 129.7× | 41.8% | +13.7% |
| Hims & Hers Health HIMS | United States | $6.07B | -8% | +28% | 0% | 128.9× | 54.9% | +73.6% |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.50B | +26% | +17% | 24% | 51.5× | 32.2% | +11.8% |
| Acadia Healthcare ACHC | United States | $3.44B | +47% | +4% | 10% | 18.7× | n/a | n/a |
| Sonic Healthcare SHL.AX | Australia | $6.87B | +6% | +14% | 9% | 16.8× | 8.6% | +3.5% |
| Fameglow 3774.HK | Hong Kong | $3.19B | n/a | +36% | 11% | n/a | 48.8% | +48.4% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.89B | -9% | -4% | 9% | 55.1× | 5.8% | +5.7% |
| Aveanna Healthcare AVAH | United States | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% | +10.2% |
| Pediatrix Medical MD | United States | $2.44B | +33% | +2% | 12% | 12.9× | -4.5% | +2.0% |
| Addus HomeCare ADUS | United States | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% | +13.2% |
| AddLife ALIF-B.ST | Sweden | $2.29B | +25% | +2% | 8% | 40.5× | 21.6% | +14.6% |
| NeoGenomics NEO | United States | $2.18B | +88% | +11% | -6% | 58.9× | n/a | n/a |
| Ensign ENSG | United States | $10.6B | +6% | +17% | 9% | 21.1× | 12.0% | +16.5% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |